Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation
NCT03414814Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Seoul National University Hospital. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03414814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414814.